Recombinant Human RCAS1 protein (His tag N-Terminus)

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RCAS1 also known as Receptor-binding Cancer Antigen expressed on SiSo cells or Estrogen Receptor Binding Fragment Associated Gene 9 (EBAG9) is a membrane-bound protein with an approximate mass of 32 kDa. It is widely expressed in various tissues including the reproductive system lungs and liver. This protein acts mechanically as a ligand for the RCAS1 receptor facilitating cell-to-cell communication through binding.

Biological function summary

RCAS1 plays a significant role in immune modulation by influencing cell death and immune response. Researchers have not classified it as being a part of any known protein complex. This protein helps regulate the immune system's ability to recognize and respond to abnormal or cancerous cells. It contributes to creating an immune-suppressive microenvironment favoring tumor growth by inhibiting the function of natural killer cells and cytotoxic T lymphocytes.

Pathways

RCAS1's functions intersect with important processes in cellular immune regulation and apoptosis. One of the major pathways involves the Fas signaling pathway where RCAS1 interacts with Fas-related proteins affecting apoptotic cell death. Through this pathway it modulates immune escape mechanisms employed by tumor cells. RCAS1 also correlates with pathways linked to inflammatory responses including its interaction with cytokines such as interferon-gamma.

RCAS1 has significant implications in oncology particularly in various cancers like breast and cervical cancer. Its expression level often shows correlation with tumor aggressiveness and poor prognosis. RCAS1's expression may engage other proteins such as progesterone receptors impacting hormone-related pathways in breast cancer. Additionally the protein's role in immune suppression indicates its potential involvement in immune escape by tumors which makes it a focus of study in cancer immunotherapy.